Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Yale University
Radiation Therapy Oncology Group
Merck Sharp & Dohme LLC
Incyte Corporation
M.D. Anderson Cancer Center
Sanofi
GERCOR - Multidisciplinary Oncology Cooperative Group
Merck Sharp & Dohme LLC
Nektar Therapeutics
Washington University School of Medicine
Washington University School of Medicine
University of Arizona
GlaxoSmithKline
University of Cincinnati
The University of Texas Health Science Center at San Antonio
Stanford University
Washington University School of Medicine
Bristol-Myers Squibb
Pfizer
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
University of Wisconsin, Madison
Celldex Therapeutics
Bristol-Myers Squibb
Radiation Therapy Oncology Group
University of Texas Southwestern Medical Center
University of Pittsburgh
Eisai Inc.
Glycotope GmbH
Bristol-Myers Squibb
Rutgers, The State University of New Jersey
University of Michigan Rogel Cancer Center
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
UNC Lineberger Comprehensive Cancer Center
Louisiana State University Health Sciences Center Shreveport
Washington University School of Medicine
University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
UNC Lineberger Comprehensive Cancer Center
University of Chicago
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Chicago